News Sentiment

NERV sentiment intelligence

Minerva Neurosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.72 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-7.5% over one week, +4.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neurosciences Inc

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -7.5% Price reacting lower
Trend fit Trend inactive 4.7% over four weeks
Fair value 18.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 40
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Stock Titan 9
Market source 6
marketscreener.com 5
GlobeNewswire 5
TradingKey 4
www.marketscreener.com 3
Zacks 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 16
Analyst action 4
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Titan Direct company coverage

Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV)

Federated Hermes, Inc. has filed an Amendment No. 1 to a Schedule 13G/A, disclosing an ownership of 8,690,926 shares of Minerva Neurosciences, Inc. common stock, which represents a 17.17% stake. The filing includes related reporting persons such as the Voting Shares Irrevocable T

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 11:40
Source
Stock Titan
Finviz Direct company coverage

NERV - Minerva Neurosciences Inc Options

This article provides a detailed financial overview of Minerva Neurosciences Inc. (NERV), including its stock performance, market capitalization, key financial ratios, and insider transaction data. It highlights various metrics such as EPS, sales, volatility, and analyst recommen

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 05:40
Source
Finviz
www.marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Dynamic Index

Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on central nervous system diseases, has been added to the Russell 2000 Dynamic Index. This inclusion is part of several other Russell index additions announced on June 29th and 28th,

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 20:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Value Benchmark

Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell Small Cap Comp Value Benchmark. This update reflects the company's inclusion in important market indices, alongside several other Russell index inclusions announced on the same day. Minerva Neurosciences i

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 16:39
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index

Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing product candidates for central nervous system (CNS) diseases, including roluperidone for schizophrenia and MIN-30

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 06:41
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Index

Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company, has been added to the Russell 3000 Index. The news, published on June 28, 2026, highlights the company's progress in developing therapies for central nervous system diseases. Minerva Neurosc

Tone
Positive 69/100
Event
Market update
Published
29 Jun 2026 03:39
Source
marketscreener.com
marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Value Benchmark

Minerva Neurosciences, Inc. (NasdaqCM: NERV), a clinical-stage biopharmaceutical company focused on CNS diseases, has been added to the Russell 2500 Value Benchmark. The company is currently developing roluperidone for schizophrenia and has rights to MIN-301 for Parkinson's disea

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 03:39
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Value Benchmark

Minerva Neurosciences, Inc. (NasdaqCM: NERV) has been added to the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This inclusion indicates an updated valuation and categorization within the financial markets. The company, a clinical-stage b

Tone
Positive 71/100
Event
Market update
Published
28 Jun 2026 19:39
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Minerva Neurosciences, Inc – NASDAQ:NERV

This article provides a financial snapshot for Minerva Neurosciences, Inc (NASDAQ: NERV), specifically highlighting its price-to-sales forward ratio. It also details navigation and product information for the TradingView platform where this data is presented. The content appears

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:39
Source
TradingView
TradingView Direct company coverage

Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV)

This article provides an overview of Minerva Neurosciences, Inc. (NASDAQ: NERV) stock, covering its current price, historical performance, analyst forecasts, and financial data. It details recent movements in stock price, market capitalization, and upcoming earnings report, along

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

NERV Forecast — Price Target — Prediction for 2027

This article provides a forecast for Minerva Neurosciences, Inc. (NERV) stock, including analyst price targets, historical performance, and financial data. Analysts estimate a maximum future price of $14.00 and a minimum of $7.00 for NERV. The company's current stock price is $4.

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 01:05
Source
TradingView
TradingView Direct company coverage

Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA)

This article provides an overview of Minerva Neurosciences Inc (FWB:4MNA) stock, including its financial actuals, analyst estimates, price forecasts, and historical price performance. It details the company's past earnings and revenue, future earnings report dates, and states tha

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

ETFs Investing in Minerva Neurosciences Inc Stocks

This article lists ETFs that invest in Minerva Neurosciences Inc (NERV) stocks, providing details such as market value, weight, issuer, and expense ratio for each fund. It highlights the Invesco NASDAQ Future Gen 200 ETF (QQQS) as one such fund, making investing in NERV more acce

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Minerva Neurosciences, Inc – NASDAQ:NERV

This article provides a brief snapshot of the "Price to earnings forward" metric for Minerva Neurosciences, Inc (NASDAQ: NERV) on TradingView. It indicates that the market was closed with no trades at the time of publication. The content also lists various features and financial

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Minerva Neurosciences, Inc – NASDAQ:NERV

This article provides financial data for Minerva Neurosciences, Inc. (NASDAQ: NERV), specifically focusing on its forward price-to-book ratio. The content is presented within the TradingView platform, indicating it's a financial data point rather than a detailed news analysis.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

4MNA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Minerva Neurosciences Inc. (4MNA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a 1-year price forecast up to 8.16 EUR, with a maximum estimate of 12.03 EUR and a mini

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 14:09
Source
TradingView
TradingKey Direct company coverage

Minerva Neurosciences Inc (NERV) Institutional Confidence

Minerva Neurosciences Inc (NERV) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 275.59% quarter-over-quarter to 71.95%. The largest institutional shar

Tone
Positive 61/100
Event
Market update
Published
18 Jun 2026 06:41
Source
TradingKey
TradingKey Direct company coverage

Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Minerva Neurosciences Inc (NERV) has an earnings forecast score of 6.67, ranking 324 out of 388 in its industry, with an average analyst price target of USD 4.50. Three analysts currently rate the stock as "Hold." Despite a previous quarter's EPS of -25.45, the next quarter expec

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:41
Source
TradingKey
TradingKey Direct company coverage

Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis

Minerva Neurosciences Inc (NERV) currently has a valuation score of 8.70, placing it 102nd out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -0.11, significantly below its recent high and above its recent low. However, releva

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:41
Source
TradingKey
TradingKey Direct company coverage

Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Minerva Neurosciences Inc (NERV), focusing on its current stock price momentum, support and resistance levels, and key indicators. It highlights NERV's momentum score, its trading range, and a predominantly "Sell" signal based on vari

Tone
Negative 39/100
Event
Market update
Published
18 Jun 2026 06:41
Source
TradingKey
Simply Wall Street Direct company coverage

Minerva Neurosciences (Nasdaq:NERV) - Stock Analysis

Minerva Neurosciences (Nasdaq:NERV) is a clinical-stage biopharmaceutical company focused on central nervous system diseases, with its lead product candidate roluperidone in a Phase 3 confirmatory trial for negative symptoms of schizophrenia. The company faces significant risks i

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 07:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800

Minerva Neurosciences' SVP, CFO, and Secretary, Frederick W. Ahlholm, was granted 680,000 employee stock options with an exercise price of $4.6800 per share, expiring on June 2, 2036. The options will vest 25% on June 3, 2027, with the remainder vesting in equal quarterly install

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 05:09
Source
Stock Titan
Stock Titan Direct company coverage

Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading

Minerva Neurosciences (NERV) director Inderjit Kaul was granted 50,000 stock options as equity compensation. The options have an exercise price of $4.68 per share and vest in four equal quarterly installments, beginning three months after June 3, 2026. Following this grant, Kaul

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Minerva Neurosciences director granted 50,000 options | NERV Insider Trading

Minerva Neurosciences director G Jan Van Heek was granted 50,000 stock options with an exercise price of $4.68 per share, expiring on June 2, 2036. The options will vest in four equal quarterly installments, contingent on his continued service as a non-employee director. This tra

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68

Minerva Neurosciences (NERV) has granted director Fouzia Laghrissi-Thode 50,000 stock options with an exercise price of $4.68 per share. The options expire on June 2, 2036, and vest in four equal quarterly installments, contingent on her continued service as a non-employee direct

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:40
Source
Stock Titan